ALACHUA, Fla.--(BUSINESS WIRE)--Banyan Biomarkers, Inc. announced today that the U.S. Patent and Trademark Office has granted U.S. Patent No. 7,291,710 “Detection of spectrin and spectrin proteolytic cleavage products in assessing nerve cell damage”, licensed exclusively by Banyan Biomarkers from the University of Florida. The detection of spectrin and spectrin breakdown products in patients’ blood will allow physicians to determine the magnitude of injury and the progression of neuronal cell death after injury, thus aiding in the diagnosis of brain injuries.
